Mechano-transduction to muscle protein synthesis is modulated by FAK

We examined the involvement of focal adhesion kinase (FAK) in mechano-regulated signalling to protein synthesis by combining muscle-targeted transgenesis with a physiological model for un- and reloading of hindlimbs. Transfections of mouse tibialis anterior muscle with a FAK expression construct increased FAK protein 1.6-fold versus empty transfection in the contralateral leg and elevated FAK concentration at the sarcolemma. Altered activation status of phosphotransfer enzymes and downstream translation factors showed that FAK overexpression was functionally important. FAK auto-phosphorylation on Y397 was enhanced between 1 and 6h of reloading and preceded the activation of p70S6K after 24h of reloading. Akt and translation initiation factors 4E-BP1 and 2A, which reside up- or downstream of p70S6K, respectively, showed no FAK-modulated regulation. The findings identify FAK as an upstream element of the mechano-sensory pathway of p70S6K activation whose Akt-independent regulation intervenes in control of muscle mass by mechanical stimuli in human

Mécanismes moléculaires du contrôle de la masse musculaire sous l'action du b2-agoniste formotérol

Les b2-agonistes sont couramment utilisés pour prévenir et réduire les symptômes de l'asthme et de la bronchoconstriction induite par l'exercice. Mais, pris en quantités supérieures aux doses thérapeutiques, les b2-agonistes ont un effet anabolisant qui a été clairement démontré in vivo. Un certain nombre d acteurs sont mis en jeu dans la réponse biologique du tissu musculaire aux b2-agonistes. L un de ces acteurs est la voie de signalisation PI3K/Akt/mTOR, voie d initiation de la traduction, ayant un rôle majeur dans la synthèse protéique. Dans ce contexte, notre première étude avait pour objectif de déterminer la cinétique des événements moléculaires responsables de l hypertrophie du muscle squelettique de rat après administration de formotérol pendant 1 jour (J1), 3 jours (J3) et 10 jours (J10). Nous avons montré que l administration de formotérol induisait une hypertrophie musculaire à J3 et J10 associée à l activation transitoire de la voie de signalisation PI3K/Akt/mTOR (J1 et J3), et à une diminution de l expression de l E3 ubiquitine ligase MAFbx/Atrogin-1 (J3). La voie autophagie lysosome ne semblait pas être affectée. Ainsi, l ensemble de ces résultats suggère que l activation de la voie PI3K/Akt/mTOR est associée à la voie ubiquitine-protéasome mais pas à la voie autophagie-lysosome. La régulation transitoire de la voie PI3K/Akt/mTOR suggère que d autres voies de signalisation sont impliquées dans l hypertrophie musculaire induite par le formotérol. Le 007-AM, analogue de l AMPc, a été décrit comme pouvant stimuler la voie de signalisation PI3K/Akt/mTOR via l activation de la protéine Epac, suggérant que le 007-AM puisse constituer une molécule de substitution à l utilisation des b2-agonistes. Notre seconde étude avait pour but de déterminer si le 007-AM avait une action anabolisante sur le tissu musculaire, mais également de déterminer si la 007-AM était une molécule stable permettant d envisager son usage dans un cadre pharmacologique. L administration de 007-AM pendant 7 jours chez des souris n engendrait pas d hypertrophie musculaire. En revanche, in vitro sur cellules C2C12, le 007-AM activait la voie de signalisation PI3K/Akt/mTOR comme en témoignait l augmentation de la phosphorylation des protéines rpS6 et 4E-BP1. Nos résultats montraient également que le 007-AM était instable dans le plasma alors que son produit de dégradation, le 007 était plus stable. Pris ensembles, ces résultats suggèrent qu un traitement de 7 jours au 007-AM n est pas suffisant pour induire une hypertrophie musculaire et que l absence d hypertrophie musculaire pourrait provenir de l instabilité du 007-AM dans le plasma. Toutefois, des études supplémentaires seront nécessaires pour confirmer ces résultats2-agonists are traditionally used to prevent and reduce asthma symptoms and bronchoconstriction induced by exercise. Nevertheless, when administrated in vivo, at relatively high, far away from therapeutic doses, b2-agonists induce anabolic effects. Numerous actors are involved in biological response of the skeletal muscle, induced by b2-agonists. PI3K/Akt/mTOR signaling pathway, which initiates translation, is one of these actors. In this context, our first study aimed at determined the kinetic of molecular events responsible for skeletal muscle hypertrophy after 1 day (D1), 3 days (D3) and 10 days (D10) of formoterol administration. We have shown that formoterol administration induced skeletal muscle hypertrophy at D3 and D10 associated with a transient activation of PI3K/Akt/mTOR signaling pathway (D1 and D3), and, with a decrease in E3 ubiquitin ligase MAFbx/atrogin-1 expression (D3). The autophagy-lysosome pathway seems not to be regulated by formoterol administration. Taken together, these results suggest that PI3K/Akt/mTOR activation is temporally associated with the regulation of ubiquitin-proteasome but not the autophagy-lysosome pathway. The transient nature of the regulation of PI3K/Akt/mTOR signaling pathway also indicates that other unidentified pathways are probably activated to sustain the increase in skeletal muscle mass. Recently, 007-AM synthetic molecule has been described to stimulate PI3K/Akt/mTOR signaling pathway through Epac protein activation, suggesting that 007-AM could be an alternative to the use of b2-agonists. The purpose of our second study was to determine whether 007-AM had an anabolic action on skeletal muscle and if 007-AM was stable allowing considering its use in pharmacology. 007-AM administration for 7 days to mice does not lead to muscle hypertrophy. Nonetheless, in vitro on C2C12 cells, 007-AM activated PI3K/Akt/mTOR signaling pathway by increasing phosphorylation of rpS6 and 4E-BP1. Our results showed that contrary to 007, 007-AM was instable in plasma. Altogether, these results suggest that a 7-day 007-AM treatment is not sufficient to induce skeletal muscle hypertrophy. This lack of hypertrophy could be due to 007-AM instability in plasma. However, supplemental studies are needed to confirm these resultsST ETIENNE-Bib. électronique (422189901) / SudocSudocFranceF

Invalidation du gène de la myostatine dans un modèle murin de cachexie associée au cancer (implication dans la régulation de la masse musculaire)

La cachexie est un syndrome clinique et métabolique caractérisé par une perte de tissu adipeux et de tissu musculaire, fréquemment observé chez les patients atteints de cancer. La myostatine (Mstn) régule négativement la masse musculaire. Bien que la régulation des mécanismes moléculaires impliqués dans le contrôle de la masse musculaire joue un rôle central dans la cachexie associée au cancer, les relations existant entre la Mstn et les mécanismes physiopathologiques restent largement inconnues. Suite à l inoculation de cellules Lewis lung carcinoma (LLC) à des souris, nous avons montré que l invalidation du gène de la Mstn (souris Mstn-/-) confère une résistance au développement de la cachexie associée au cancer par rapport à des souris sauvages. La déficience en Mstn prévient la perte de masse musculaire et réduit la croissance tumorale, 35 jours après l injection des cellules LLC, et est associée à un allongement de la durée de vie des souris. L invalidation du gène de la Mstn provoque aussi une augmentation de l apoptose des cellules LLC et une diminution de l'expression de gènes impliqués dans la prolifération et le métabolisme tumoraux. L activation des systèmes protéolytiques ubiquitine-protéasome et autophagie-lysosome, due au développement tumoral, est réduite voire supprimée dans le muscle des souris Mstn-/-. L accumulation de céramides intramusculaires, un sphingolipide formé suite à une lipolyse exacerbée, est corrélée à la perte de masse musculaire, suggérant que les céramides pourraient être un médiateur cellulaire impliqué dans la cachexie associée au cancer. Ces résultats montrent que la Mstn joue un rôle essentiel dans la cachexie associée au cancerCachexia is a complex clinical and metabolic syndrome, whose definition is imprecise, characterized by an uncontrolled loss of adipose tissue and skeletal muscle mass, frequently observed in cancer patients, and leading to death in 25% of cancer patients. Myostatin (Mstn) is a negative regulator of skeletal muscle mass and a critical determinant of skeletal muscle homeostasis. Although the regulation of the molecular mechanisms involved in the control of skeletal muscle mass plays a central role in the pathogenesis of cancer cachexia, the relationships between Mstn and the pathophysiological mechanisms remain largely unknown. Following subcutaneous inoculation of Lewis lung carcinoma cells (LLC) in mice, we showed that the Mstn gene inactivation (Mstn-/- mice) confers resistance to the development of cancer cachexia, compared to wild type mice. Mstn deficiency prevents the loss of skeletal muscle mass and reduces tumor growth, 35 days after the inoculation of LLC cells, and this is associated with a longer life of mice. Mstn gene inactivation also causes an increased apoptosis of LLC cells and decreases expression of genes involved in tumor proliferation and metabolism. Activation of ubiquitin-proteasome and autophagy-lysosome proteolytic systems, triggered by tumor growth is significantly reduced or suppressed in skeletal muscle of Mstn-/- mice. Accumulation of intramuscular ceramides, a sphingolipid synthesized due to excessive lipolysis, is correlated with the loss of muscle mass, suggesting that ceramides may be a cellular mediator involved in the pathogenesis of cancer cachexia. These results show that Mstn plays a critical role in the pathogenesis of cancer cachexiaST ETIENNE-Bib. électronique (422189901) / SudocSudocFranceF

Energetic status and mitochondrial oxidative capacity of rat skeletal muscle in response to creatine analogue ingestion

AbstractA creatine analogue, β-guanidinopropionic acid (α-GPA), was administered in the food (1% w/w) of 8 male rats for 6 weeks, while 8 control rats received a standard diet. Mitochondrial oxidative capacity and cytosolic modulators of mitochondrial oxidative phosphorylation (free ADP, ATP-to-free ADP ratio) were evaluated in the soleus and extensor digitorum longus (EDL) muscles. Mitochondrial adaptation to the diet was significantly different between muscles. Citrate synthase activity and mitochondrial ATP synthesis rate were 35 and 45% higher in EDL muscle, respectively, whereas they were virtually unchanged in the soleus muscle. In both muscles, 3-hydroxyacyl-CoA dehydrogenase activity remained unaffected. Regardless of muscle type, creatine, phosphocreatine and ATP concentrations, as well as the total adenine nucleotide content (ATP + ADP + AMP), were significantly lower in β-GPA fed rats. Whereas free ADP concentration remained unchanged, a significantly greater decrease in ATP-to-free ADP ratio was observed in EDL than in the soleus muscle. It is suggested that regulation of mitochondrial oxidative phosphorylation, through changes in metabolite concentrations, could be an important factor to consider for mitochondrial adaptation induced by β-GPA feeding

Mechano-transduction to muscle protein synthesis is modulated by FAK

We examined the involvement of focal adhesion kinase (FAK) in mechano-regulated signalling to protein synthesis by combining muscle-targeted transgenesis with a physiological model for un- and reloading of hindlimbs. Transfections of mouse tibialis anterior muscle with a FAK expression construct increased FAK protein 1.6-fold versus empty transfection in the contralateral leg and elevated FAK concentration at the sarcolemma. Altered activation status of phosphotransfer enzymes and downstream translation factors showed that FAK overexpression was functionally important. FAK auto-phosphorylation on Y397 was enhanced between 1 and 6 h of reloading and preceded the activation of p70S6K after 24 h of reloading. Akt and translation initiation factors 4E-BP1 and 2A, which reside up- or downstream of p70S6K, respectively, showed no FAK-modulated regulation. The findings identify FAK as an upstream element of the mechano-sensory pathway of p70S6K activation whose Akt-independent regulation intervenes in control of muscle mass by mechanical stimuli in humans

Muscle inactivation of mTOR causes metabolic and dystrophin defects leading to severe myopathy

Mammalian target of rapamycin (mTOR) is a key regulator of cell growth that associates with raptor and rictor to form the mTOR complex 1 (mTORC1) and mTORC2, respectively. Raptor is required for oxidative muscle integrity, whereas rictor is dispensable. In this study, we show that muscle-specific inactivation of mTOR leads to severe myopathy, resulting in premature death. mTOR-deficient muscles display metabolic changes similar to those observed in muscles lacking raptor, including impaired oxidative metabolism, altered mitochondrial regulation, and glycogen accumulation associated with protein kinase B/Akt hyperactivation. In addition, mTOR-deficient muscles exhibit increased basal glucose uptake, whereas whole body glucose homeostasis is essentially maintained. Importantly, loss of mTOR exacerbates the myopathic features in both slow oxidative and fast glycolytic muscles. Moreover, mTOR but not raptor and rictor deficiency leads to reduced muscle dystrophin content. We provide evidence that mTOR controls dystrophin transcription in a cell-autonomous, rapamycin-resistant, and kinase-independent manner. Collectively, our results demonstrate that mTOR acts mainly via mTORC1, whereas regulation of dystrophin is raptor and rictor independent

Muscle inactivation of mTOR causes metabolic and dystrophin defects leading to severe myopathy

mTor, acting mainly via mTORC1, controls dystrophin transcription in a raptor- and rictor-independent mechanism

Phenotypic features of cancer cachexia‐related loss of skeletal muscle mass and function: lessons from human and animal studies

Abstract Cancer cachexia is a complex multi‐organ catabolic syndrome that reduces mobility, increases fatigue, decreases the efficiency of therapeutic strategies, diminishes the quality of life, and increases the mortality of cancer patients. This review provides an exhaustive and comprehensive analysis of cancer cachexia‐related phenotypic changes in skeletal muscle at both the cellular and subcellular levels in human cancer patients, as well as in animal models of cancer cachexia. Cancer cachexia is characterized by a major decrease in skeletal muscle mass in human and animals that depends on the severity of the disease/model and the localization of the tumour. It affects both type 1 and type 2 muscle fibres, even if some animal studies suggest that type 2 muscle fibres would be more prone to atrophy. Animal studies indicate an impairment in mitochondrial oxidative metabolism resulting from a decrease in mitochondrial content, an alteration in mitochondria morphology, and a reduction in mitochondrial metabolic fluxes. Immuno‐histological analyses in human and animal models also suggest that a faulty mechanism of skeletal muscle repair would contribute to muscle mass loss. An increase in collagen deposit, an accumulation of fat depot outside and inside the muscle fibre, and a disrupted contractile machinery structure are also phenotypic features that have been consistently reported in cachectic skeletal muscle. Muscle function is also profoundly altered during cancer cachexia with a strong reduction in skeletal muscle force. Even though the loss of skeletal muscle mass largely contributes to the loss of muscle function, other factors such as muscle–nerve interaction and calcium handling are probably involved in the decrease in muscle force. Longitudinal analyses of skeletal muscle mass by imaging technics and skeletal muscle force in cancer patients, but also in animal models of cancer cachexia, are necessary to determine the respective kinetics and functional involvements of these factors. Our analysis also emphasizes that measuring skeletal muscle force through standardized tests could provide a simple and robust mean to early diagnose cachexia in cancer patients. That would be of great benefit to cancer patient's quality of life and health care systems